Bulletin from the Extraordinary General Meeting in Nexam Chemical Holding AB (publ) on January 19 2026

Nexam Chemical’s extraordinary general meeting approved a rights issue expected to raise approximately SEK 58.1 million before costs, offering 4 new shares for every 15 subscription rights at SEK 2.40 per share (maximum 21,577,544 shares) with a subscription period of 26 January–9 February 2026. The AGM also authorised the Board to issue shares to guarantors (at VWAP during the subscription period, not below SEK 2.40) as compensation for guarantee commitments and to implement an over-allotment issue of up to 6,250,000 additional shares at SEK 2.40, measures intended to secure the financing and ensure allotment to top guarantors but that will dilute existing shareholders.

Analysis

Market structure: The rights issue (SEK 58.1m at SEK 2.40, subscription 26 Jan–9 Feb 2026, record date 22 Jan) directly benefits guarantors/top-guarantors (who receive fee shares) and new capital providers who subscribe; non‑participating existing shareholders face dilution and potential short-term selling. The incremental supply (up to 21.6m shares + 6.25m over-allotment) increases free float and raises the probability of downward pressure in the 0–6 week window post-closing; competitors in specialty additives see negligible direct change to pricing power unless Nexam uses proceeds for aggressive commercial expansion.

Risk assessment: Tail risks include a rights undersubscription that forces guarantor issuances and immediate block disposals (high impact, low prob) and failure to convert R&D into commercial contracts (medium prob, high impact). Immediate effect (days): volatility around record/subscription dates; short-term (weeks/months): price discovery as guarantors monetize; long-term (6–24 months): depends on whether SEK 58m buys identifiable revenue-generating milestones. Hidden dependency: guarantor VWAP-based issuance creates timing incentives to sell into strength, amplifying volatility.

Trade implications: Direct: small-cap tactical trades—either subscribe/accumulate rights or short pre-close. Options: preferrable to use put-spreads (e.g., Mar/Jun 2026 2.40/1.60) to limit capital on illiquid options markets. Pair trade: rotate out of NEXAM.ST into larger, cash-generative specialty polymer names (e.g., HEXPOL B (HEXAB.ST)) to reduce idiosyncratic dilution risk.

Contrarian angles: The market may overprice dilution risk—if subscription rate >70–80% and no >5% block sales by guarantors within 30 days, upside re-rating is plausible when 6–12 month commercial milestones are announced. Historical parallel: small-cap rights issues typically drop 20–40% then recover if proceeds fund demonstrable sales wins; unintended consequence of the authorisations is concentrated post-issue ownership that can either stabilize or trigger rapid disposals depending on guarantor incentives.

Key Decisions for Investors

• Establish a tactical long via rights subscription only: allocate 1–2% NAV to subscribe at SEK 2.40 (commit by 9 Feb 2026). If you cannot subscribe, limit open-market buys to <0.5% NAV and wait for post-issue price action (>30% discount to SEK 2.40 or clear commercial news).
• Establish a small hedge/short: initiate a 0.5–1.5% NAV short position in NEXAM.ST beginning 48–72 hours before subscription close (26 Jan–9 Feb) to capture likely pre/post-issue pressure; cover if subscription rate announced >80% or price rallies above SEK 3.50 within 10 trading days after settlement.
• Pair trade: rotate 2–3% NAV from NEXAM.ST into HEXPOL B (HEXAB.ST) or a large-cap European specialty polymer name for 6–12 months to preserve sector exposure while reducing dilution/operational risk; target a relative performance hedge of +300–500 bps.
• If liquid, buy protective put-spreads on NEXAM.ST (Mar/Jun 2026 2.40/1.60 or nearest strikes) sized to cap downside to ~1% NAV; if options are illiquid, use CFDs or swaps. Monitor: subscription outcome (by 9 Feb), VWAP announcement, and any guarantor block sales >5% float within 30 days—if any occur, increase short to 2–3% NAV.